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Background: Combination therapy with oral fluoropyrimidine and irinotecan has not yet been established as first-line
treatment of metastatic colorectal cancer (mCRC). We carried out a randomized, open-label, phase III trial to determine whether
S-1 and irinotecan plus bevacizumab is noninferior to mFOLFOX6 or CapeOX plus bevacizumab in terms of progression-free
survival (PFS).
Patients and methods: Patients from 53 institutions who had previously untreated mCRC were randomly assigned (1 : 1) to
receive either mFOLFOX6 or CapeOX plus bevacizumab (control group) or S-1 and irinotecan plus bevacizumab (experimental
group; a 3-week regimen: intravenous infusions of irinotecan 150mg/m2 and bevacizumab 7.5mg/kg on day 1, oral S-1 80mg/
m2 twice daily for 2weeks, followed by a 1-week rest; or a 4-week regimen: irinotecan 100mg/m2 and bevacizumab 5mg/kg on
days 1 and 15, S-1 80mg/m2 twice daily for 2weeks, followed by a 2-week rest). The primary end point was PFS. The
noninferiority margin was 1.25; noninferiority would be established if the upper limit of the 95% confidence interval (CI) for the
hazard ratio (HR) of the control group versus the experimental group was less than this margin.
Result: Between June 2012 and September 2014, 487 patients underwent randomization. Two hundred and forty-three
patients assigned to the control group and 241 assigned to the experimental group were included in the primary analysis.
Median PFS was 10.8months (95% CI 9.6–11.6) in the control group and 14.0months (95% CI 12.4–15.5) in the experimental
group (HR 0.84, 95% CI 0.70–1.02; P< 0.0001 for noninferiority, P¼ 0.0815 for superiority). One hundred and fifty-seven patients
(64.9%) in the control group and 140 (58.6%) in the experimental group had adverse events of grade 3 or higher.
VC The Author(s) 2017. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
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Conclusion: S-1 and irinotecan plus bevacizumab is noninferior to mFOLFOX6 or CapeOX plus bevacizumab with respect to
PFS as first-line treatment of mCRC and could be a new standard treatment.
Clinical trials number: UMIN000007834
Key words: IRIS, SIRB, FOLFOX, XELOX, mCRC
Introduction
FOLFOX, CapeOX, or FOLFIRI plus bevacizumab are extensively
used as first-line treatment of metastatic colorectal cancer
(mCRC) [1, 2]. Oxaliplatin-based combination regimens such as
FOLFOX and CapeOX are commonly used in general clinical prac-
tice in many countries, including Japan and the United States, in
preference to FOLFIRI, because the resulting alopecia and gastro-
intestinal toxicity are milder. However, peripheral neuropathy
induced by oxaliplatin often leads to treatment withdrawal, nega-
tively affecting treatment continuity. Furthermore, peripheral neu-
ropathy is usually prolonged, interfering with the daily lives of
patients and reducing their quality of life (QOL) [1, 3].
Meanwhile, combination therapy with an oral fluoropyrimidine
and irinotecan as first-line treatment of mCRC has not yet been
established [4].
The oral fluoropyrimidine S-1 has been approved in Japan; the
European Medicines Agency has approved S-1 for gastric cancer.
S-1 is a combined preparation consisting of tegafur, a prodrug of
5-fluorouracil (5-FU), and the modulators gimeracil and oteracil
potassium [5]. S-1 plus irinotecan was shown to be noninferior to
FOLFIRI as second-line chemotherapy for mCRC [6, 7]. Two
phase II studies have evaluated 3-week and 4-week regimens of S-1
combined with irinotecan plus bevacizumab as first-line chemo-
therapy for mCRC; promising outcomes were obtained [8, 9].
On the basis of these studies, we examined whether S-1 and irino-
tecan plus bevacizumab was noninferior in terms of progression-
free survival (PFS) to mFOLFOX6 or CapeOX plus bevacizumab as
first-line chemotherapy for mCRC.
Methods
Study design
The TRICOLORE trial was an open-label, multicenter, randomized
phase III trial conducted in Japan in patients who previously untreated
mCRC. This study was conducted in accordance with the ethical princi-
ples of the Declaration of Helsinki and complied with the Japanese ethical
guidelines for clinical studies. The study was approved by the institu-
tional review board of each participating institution.
Participants
The main inclusion criteria were as follows: histologically confirmed col-
orectal adenocarcinoma; unresectable mCRC; age 20 years or older;
ECOG performance status of 0 or 1; no previous chemotherapy or radio-
therapy; adequate oral intake; and adequate organ function. The main
exclusion criteria were as follows: sensory neuropathy; serious diarrhea;
gastrointestinal obstruction; symptomatic peritoneal metastasis; and a
history of gastrointestinal perforation within the 6 months before enroll-
ment. All patients provided written informed consent before enrollment.
The details of the criteria have been reported previously [10].
Randomization and masking
Participants were randomly assigned (1 : 1) to receive either mFOLFOX6
or CapeOX plus bevacizumab (control group) or to receive either a 3-
week or a 4-week regimen of S-1 and irinotecan plus bevacizumab
(experimental group). Each participating institution could select either
mFOLFOX6 plus bevacizumab or CapeOX plus bevacizumab and either
a 3-week or 4-week regimen of S-1 and irinotecan plus bevacizumab.
After reporting to the data center (AC Medical Inc., Tokyo, Japan),
patient enrollment was initiated (supplementary Figure S1, available at
Annals of Oncology online). Randomization was performed centrally
using the minimization method with the following stratification factors:
institution; adjuvant chemotherapy (none, including oxaliplatin, or not
including oxaliplatin); and the number of metastatic organs (0 or 1
versus2).
Procedures
The mFOLFOX6 plus bevacizumab regimen consisted of bevacizumab
(5 mg/kg) given as an intravenous infusion on day 1 of each 2-week cycle,
followed by a simultaneous intravenous infusion of oxaliplatin (85 mg/m2)
plus l-leucovorin (200 mg/m2), an intravenous bolus 5-FU (400 mg/m2),
and a continuous intravenous infusion of 5-FU (2400 mg/m2). The
CapeOX plus bevacizumab regimen consisted of bevacizumab (7.5 mg/kg)
given as an intravenous infusion on day 1 of each 3-week cycle, followed by
an intravenous infusion of oxaliplatin (130 mg/m2). Capecitabine
(1000 mg/m2) was taken orally twice daily, from after dinner on day 1 to
after breakfast on day 15, followed by a 7-day rest. The 3-week S-1 and iri-
notecan plus bevacizumab regimen consisted of bevacizumab (7.5 mg/kg)
given as an intravenous infusion on day 1 of each 3-week cycle, followed by
an intravenous infusion of irinotecan (150 mg/m2). S-1 (40 mg/m2) was
taken orally twice daily, from after dinner on day 1 to after breakfast on day
15, followed by a 7-day rest. The 4-week S-1 and irinotecan plus bevacizu-
mab regimen consisted of bevacizumab (5 mg/kg) given as an intravenous
infusion on day 1 and day 15 of each 4-week cycle, followed by an intrave-
nous infusion of irinotecan (100 mg/m2). S-1 (40 mg/m2) was taken orally
twice daily, from after dinner on day 1 to after breakfast on day 15, followed
by a 14-day rest. Cycles were repeated for each patient until criteria for
withdrawal of the study treatment were met. For the mFOLFOX6 plus bev-
acizumab and CapeOX plus bevacizumab regimens, oxaliplatin-induced
sensory neuropathy was taken into consideration, and treatment could be
skipped if patients had received at least 600 mg/m2 of oxaliplatin overall.
The details of dose modifications have been reported previously [10].
Tumor assessment by means of diagnostic imaging was carried out
every 8 weeks, and tumor responses were assessed according to RECIST
version 1.1. Observed adverse events were evaluated according to CTCAE
v4.0. QOL was assessed according to FACT-C TOI scale and FACT/
GOG-Ntx scale before the start of treatment and at 16 and 24 weeks.
Outcomes
The primary end point was PFS, defined as the period from the date of
enrollment to the date of disease progression or of death from any cause
without progression, whichever came first. Secondary end points were
overall survival, time to treatment failure (TTF), response rate, adverse
events, QOL, quality-adjusted life years (QALYs), cost-effectiveness, and
biomarker analysis.
Annals of Oncology Original article
Volume 29 | Issue 3 | 2018 doi:10.1093/annonc/mdx816 | 625
Downloaded from https://academic.oup.com/annonc/article-abstract/29/3/624/4779925
by Kyoto Daigaku Bungakubu Toshokan user
on 14 May 2018
Statistical analysis
On the basis of the results of previous studies, the median PFS was esti-
mated to be 11 months for the control group and 12 months for the
experimental group [hazard ratio (HR), 0.917]. Given that the permissi-
ble limit for the HR was 1.25, with a statistical power of 85%, an alpha
level of 0.025 (one-sided), an enrollment period of 36 months, and a
follow-up period of 18 months for the primary end point of PFS, we esti-
mated that 434 patients would be required (required number of events,
374). To compensate for ineligible patients, the target number of patients
was set at 450. Thus, noninferiority would be established if the upper
limit of the 95% confidence interval (CI) for the HR of the control group
versus the experimental group was <1.25. If noninferiority was demon-
strated in the study, superiority would be tested. The primary analysis
was conducted using the full analysis set on an intention-to-treat basis.
We estimated time-dependent events using the Kaplan–Meier
method. We calculated HRs and their CIs with Cox proportional-
hazards models and adjusted for stratification factors (excluding institu-
tions) and treatment groups as covariates. Patients who received at least
one dose of the assigned study drugs were included in the analyses of dose
intensity and safety. QOL analysis was conducted using data from
patients in the safety analysis population for whom the pretreatment
QOL could be evaluated.
All statistical analyses were carried out using SAS, version 9.4 (SAS
Institute, Cary, NC). This trial is registered with UMIN-CTR (http://
www.umin.ac.jp/ctr/) (000007834).
Results
From 1 June 2012 through 16 September 2014, 487 patients from
53 institutions were randomly assigned, 244 patients to the control
group and 243 patients to the experimental group (supplementary
Figure S2, available at Annals of Oncology online). Two patients
who were confirmed to have no colorectal adenocarcinoma after
randomization and one patient who withdrew consent were
excluded from the primary analysis. The cut-off date for primary
analysis of the primary end point was 30 April 2016. Demographic
characteristics were similar in both groups (Table 1).
The median follow-up period was 32.4 months (range 1.5–
46.6). During this period, PFS events occurred in 426 (88%) of
484 patients. While the median PFS was 10.8 months (95% CI
9.6–11.6) in the control group, it was 14.0 months (95% CI 12.4–
15.5) in the experimental group (HR 0.84, 95% CI 0.70–1.02).
The upper limit of the HR for PFS was lower than the prespecified
noninferiority margin of 1.25 (P< 0.0001 for noninferiority,
P¼ 0.0815 for superiority; Figure 1A). The details of PFS for each
chemotherapy regimen are given in supplementary Figure S3,
available at Annals of Oncology online. In the subgroup analysis of
PFS, significant interactions were observed between the allocated
groups and age (supplementary Figure S4, available at Annals of
Oncology online). Median TTF in the control group and the
experimental group was 7.7 months (95% CI 7.1–8.2) and
9.6 months (95% CI 8.2–11.0), respectively (HR 0.71, 95% CI
0.59–0.85, P¼ 0.0002; Figure 1B). Treatment status in each group
is presented in supplementary Table S1, available at Annals of
Oncology online. The response rate of target lesions was 70.6% in
the control group and 66.4% in the experimental group
(P¼ 0.34; supplementary Table S2, available at Annals of
Oncology online). The curative resection rate was 8.6% in the
control group and 12.4% in the experimental group (P¼ 0.17).
Overall survival analysis was conducted on the basis of 218 deaths
(45%) among 484 patients. The median survival time in the con-
trol group and the experimental group was 33.6 months (95% CI
29.8–40.1) and 34.9 months (95% CI 31.9–42.4), respectively
(HR 0.86, 95% CI 0.66–1.13, P¼ 0.2841; Figure 1C).
Adverse events are summarized in Table 2. The incidences of
grade 3 or higher leukopenia, neutropenia, febrile neutropenia,
thromboembolism, and diarrhea were significantly higher in the
experimental group than in the control group. In post hoc analy-
ses, the incidences of grade 3 or higher diarrhea in patients with a
creatinine clearance (CCr) of 70 ml/min or higher and patients
with a CCr of<70 ml/min at enrollment were, respectively, 6.7%
and 6.5% in the control group as compared with 11.5% and
19.6% in the experimental group. The incidences of grade 3 or
higher sensory neuropathy, hand–foot syndrome, and paralytic
ileus were significantly higher in patients receiving the control
treatment than in those receiving the experimental treatment.
Further information on the types of adverse events occurring in
each treatment regimen is given in supplementary Table S3, avail-
able at Annals of Oncology online. There was one treatment-
related death among patients given the CapeOX regimen and
four treatment-related deaths among patients given the S-1 and
irinotecan plus bevacizumab regimen.
Before treatment, 436 (90.6%) patients completed the QOL
questionnaire. There was no statistically significant difference in
the FACT-C TOI score trends over time between the control
group and the experimental group (P¼ 0.74; Figure 2A).
However, the FACT/GOG-Ntx scores showed a significantly
more favorable trend over time in the experimental group
(P< 0.01; Figure 2B).
The number of patients in whom the study treatment was dis-
continued by the data cut-off date was 235 in the control group
and 226 in the experimental group. Among the patients whose
study treatment was discontinued, second-line treatment was
given to 206 patients (87.7%) in the control group and 198
patients (87.6%) in the experimental group. Oxaliplatin, irinote-
can, bevacizumab, and EGFR antibodies were, respectively,
administered to 12 (5.8%), 125 (60.7%), 111 (53.9%), and 26
(12.6%) patients in the control group and 112 (56.6%), 22
(11.1%), 106 (53.5%), and 20 (10.1%) patients in the experimen-
tal group. In addition, 106 (53.5%) patients in the experimental
group were given an oral fluoropyrimidine.
A more detailed analysis of QOL will be reported separately.
QALY, cost-effectiveness, and biomarker analysis will be reported
after the conclusion of follow-up in September 2017.
Discussion
To the best of our knowledge, the TRICOLORE trial is the first
randomized phase III study to demonstrate the effectiveness of
combination therapy with an oral fluoropyrimidine and irinote-
can as first-line treatment of mCRC. In this study, we established
the noninferiority of S-1 and irinotecan plus bevacizumab in
terms of PFS to the standard regimen of mFOLFOX6 or CapeOX
plus bevacizumab as first-line treatment of mCRC. Although
superiority could not be proven, the median PFS was 3.2 months
longer in the experimental group than in the control group (HR
0.84, 95% CI 0.69–1.01), and the QOL results were favorable. In
addition, S-1 and irinotecan plus bevacizumab prolonged
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median TTF by 1.9 months (HR 0.71, 95% CI 0.59–0.85), with
statistical significance.
The incidences of adverse events associated with each regimen
were similar to the results of previous studies [2, 8, 9]. The inci-
dence of grade 3 or higher diarrhea (13.4%) in the S-1 and irino-
tecan plus bevacizumab group was similar to that previously
reported for first-line treatment with FOLFIRI plus bevacizumab
(approximately 10%–14%), which was considered to demon-
strate its tolerability [11, 12]. In patients with reduced renal
function, the clearance of gimeracil in S-1 is decreased, causing
an increase in the blood concentration of FU as well as an
increased incidence of related adverse reactions. In our study, in
patients given S-1 and irinotecan plus bevacizumab whose CCr
was<70 ml/min at enrollment, the incidence of grade 3 or higher
diarrhea was 19.6%, which was higher than the incidence in
patients whose CCr was 70 ml/min or higher (11.5%). UGT1A1
gene polymorphism, one of the risk factors for irinotecan-
induced serious adverse reactions, was not assessed in our study;
Table 1. Baseline characteristics
mFOLFOX6 or CapeOX plus bevacizumab S-1 and irinotecan plus bevacizumab
(n5 243) (n5 241)
n (%) n (%)
Sex
Male 143 (58.8) 151 (62.7)
Female 100 (41.2) 90 (37.3)
PS (ECOG)
0 205 (84.4) 204 (84.6)
1 38 (15.6) 37 (15.4)
Age
Median [range] 65 [29–85] 64 [22–87]
65 134 (55.1) 118 (49.0)
CCr at enrollment
Median [range] 80.9 [60.0–153.1] 82.7 [60.0–182.8]
70 181 (74.5) 185 (76.8)
Complications
Yes 107 (44.0) 108 (44.8)
No 136 (56.0) 133 (52.2)
Adjuvant chemotherapy for colorectal cancer
Yes 31 (12.8) 32 (13.3)
No 212 (87.2) 209 (86.7)
Differentiation assessed by histology
Well or moderate 212 (87.2) 209 (86.7)
Poorly 14 (5.8) 14 (5.8)
Other 17 (7.0) 18 (7.5)
Primary lesion
Colon 122 (50.2) 130 (53.9)
Rectosigmoid 39 (16.0) 32 (13.3)
Rectum 82 (33.7) 79 (32.8)
Primary lesion resection
Yes 164 (67.5) 156 (64.7)
No 79 (32.5) 85 (35.3)
Metastatic organs
0–1 124 (51.0) 127 (52.7)
2 119 (49.0) 114 (47.3)
Target lesion
Yes 221 (90.9) 214 (88.8)
No 22 (9.1) 27 (11.2)
RAS status
Wild type 99 (40.7) 105 (43.6)
Mutant type 65 (26.7) 58 (24.1)
Not deﬁnable 6 (2.5) 3 (1.2)
Missing data 73 (30.0) 75 (31.1)
CCr, creatinine clearance.
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Figure 1. Kaplan–Meier curves for (A) progression-free survival, (B) time to treatment failure, and (C) overall survival.
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however, this factor may have affected the incidences of diarrhea
and neutropenia [13]. We believe that the safety of S-1 and irino-
tecan plus bevacizumab can be further enhanced by modifying
the initial S-1 dosage depending on renal function, modifying the
initial irinotecan dosage depending on UGT1A1 gene polymor-
phism, providing patient education, and appropriately managing
adverse events.
Peripheral neuropathy, an adverse event that interferes with
daily life, occurred in 92.1% of the patients in the control group.
QOL analysis has shown that peripheral neuropathy not only
impairs QOL and interferes with daily life, but also renders the
continuation of oxaliplatin administration impracticable and
affects efficacy. Similar to previous studies using oxaliplatin as
first-line treatment of mCRC, the administration period of oxali-
platin in our study was 24 weeks; however, it was possible to con-
tinue the administration of irinotecan for up to approximately
40 weeks or up to discontinuation of the study treatment, and we
believe that this contributed to the prolongation of TTF and PFS
in the experimental group [1].
The median PFS obtained with mFOLFOX6 or CapeOX plus
bevacizumab in our study was similar to the median PFS of
approximately 10–11 months obtained in a previous study of
fluoropyrimidine and oxaliplatin plus bevacizumab [1, 2]; how-
ever, the reported median PFS in that study of fluoropyrimidine
and irinotecan plus bevacizumab was 1.5 months longer than
the median PFS obtained with fluoropyrimidine and oxaliplatin
plus bevacizumab (HR approximately 0.9); moreover, in our
study the median PFS obtained with S-1 and irinotecan plus
bevacizumab was longer by 3.2 months (HR¼ 0.84) [14]. These
results suggest that the combination regimen of S-1 and irinote-
can plus bevacizumab can be an effective first-line treatment of
mCRC.
Table 2. Adverse events
mFOLFOX6 or CapeOX plus bevacizumab S-1 and irinotecan plus bevacizumab P valuea
(n5 242) (n5 239)
Any Grade 3 Any Grade 3
n (%) n (%) n (%) n (%)
Patients with at least 1 AE 242 (100.0) 157 (64.9) 236 (98.7) 140 (58.6) 0.16
Laboratory ﬁndings
Leukopenia 154 (63.6) 6 (2.5) 157 (65.7) 21 (8.8) <0.01
Neutropenia 139 (57.4) 33 (13.6) 150 (62.8) 58 (24.3) <0.01
Thrombocytopenia 151 (62.4) 4 (1.7) 74 (31.0) 2 (0.8) 0.69
Anemia 92 (38.0) 5 (2.1) 121 (50.6) 12 (5.0) 0.09
Bilirubin 80 (33.1) 6 (2.5) 104 (43.5) 8 (3.3) 0.60
AST 119 (49.2) 8 (3.3) 80 (33.5) 5 (2.1) 0.58
ALT 82 (33.9) 6 (2.5) 84 (35.1) 5 (2.1) 1.00
Creatinine 30 (12.4) 2 (0.8) 30 (12.6) 2 (0.8) 1.00
Proteinuria 107 (44.2) 7 (2.9) 103 (43.1) 6 (2.5) 1.00
Clinical ﬁndings
Mucositis/stomatitis 104 (43.0) 4 (1.7) 128 (53.6) 7 (2.9) 0.38
Anorexia 149 (61.6) 16 (6.6) 143 (59.8) 16 (6.7) 1.00
Nausea 119 (49.2) 9 (3.7) 136 (56.9) 8 (3.3) 1.00
Vomiting 37 (15.3) 4 (1.7) 59 (24.7) 5 (2.1) 0.75
Diarrhea 109 (45.0) 16 (6.6) 149 (62.3) 32 (13.4) 0.02
Rash/desquamation 39 (16.1) 1 (0.4) 50 (20.9) 0 (0.0) 1.00
Hyperpigmentation 99 (40.9) – – 100 (41.8) – – –
Hand–foot syndrome 125 (51.7) 15 (6.2) 59 (24.7) 2 (0.8) <0.01
Fatigue 149 (61.6) 12 (5.0) 142 (59.4) 9 (3.8) 0.66
Peripheral sensory neuropathy 223 (92.1) 53 (21.9) 47 (19.7) 0 (0.0) <0.01
Alopecia 30 (12.4) – – 143 (59.8) – – –
Watery eye 2 (0.8) 0 (0.0) 18 (7.5) 3 (1.3) 0.12
Hypertension 86 (35.5) 29 (12.0) 76 (31.8) 20 (8.4) 0.23
Paralytic ileus 8 (3.3) 7 (2.9) 2 (0.8) 0 (0.0) 0.02
Febrile neutropenia 0 (0.0) 0 (0.0) 8 (3.3) 8 (3.3) <0.01
Thromboembolism 5 (2.1) 2 (0.8) 10 (4.2) 9 (3.8) 0.04
Hemorrhage, nose 28 (11.6) 0 (0.0) 40 (16.7) 0 (0.0) –
Gastrointestinal perforation 3 (1.2) 3 (1.2) 0 (0.0) 0 (0.0) 0.25
aComparison of the frequency of adverse events of grade 3 or higher in the two groups.
AE, adverse events; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
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PFS was found to have an interaction with age in our study.
Although an interaction was not demonstrated, patients given S-
1 and irinotecan plus bevacizumab who had a CCr of 70 ml/min
or higher at enrollment tended to have favorable results. It is
therefore possible that elderly patients with decreased renal func-
tion did not receive sufficient S-1 because of adverse events. On
the other hand, non-elderly patients might benefit from aggres-
sive S-1 and irinotecan plus bevacizumab regimens.
About 53.5% of patients who initially receive S-1 (an oral fluo-
ropyrimidine) and irinotecan plus bevacizumab regimens are
also given oral fluoropyrimidines as second-line chemotherapy;
first-line and second-line treatments for mCRC given orally and
without the use of central venous ports are considered very bene-
ficial for both patients and medical practitioners.
Our study had several limitations. The benefit of using S-1 and
irinotecan plus bevacizumab as compared with FOLFIRI plus bev-
acizumab as first-line therapy for mCRC was not confirmed,
because we conducted a comparative phase III study in which the
most commonly used regimen, namely mFOLFOX6 or CapeOX
plus bevacizumab, was given to the control group. However, the
noninferiority of S-1 and irinotecan to FOLFIRI as second-line
therapy has already been demonstrated [7]. Furthermore, the
median PFS (14.0 months) obtained with S-1 and irinotecan plus
bevacizumab in our study is longer than in that in any previous
randomized controlled trial and compares favorably not only with
the results obtained in the control arm of FOLFIRI plus bevacizu-
mab in TRIBE (9.7 months), but also with the results obtained in
the trial arm of FOLFOXIRI plus bevacizumab (12.1 months).
Another potential limitation is that we do not know whether our
results can be simply extrapolated to a Western population,
because the pharmacokinetics and pharmacodynamics of S-1
might vary, and the approved dose of irinotecan (150 mg/m2, every
2 weeks) in Japan is lower than that in Western countries. If S-1
combined with irinotecan plus bevacizumab is used as chemother-
apy in Western patients, the dose should be carefully adjusted.
Conclusion
In conclusion, we consider S-1 and irinotecan plus bevacizumab
to be an effective first-line therapy for mCRC and believe that it
can be included as one of the recommended standard regimens.
Acknowledgements
We thank all the patients, their families, the investigators, and

































mFOLFOX6 or CapeOX plus bevacizumab
mFOLFOX6 or CapeOX plus bevacizumab
S-1 and irinotecan plus bevacizumab
mFOLFOX6 or CapeOX plus bevacizumab
S-1 and irinotecan plus bevacizumab
S-1 and irinotecan plus bevacizumab
mFOLFOX6 or CapeOX plus bevacizumab
S-1 and irinotecan plus bevacizumab
16 weeks 24 weeks











Figure 2. Quality of life assessed by (A) FACT-C TOI and (B) FACT/GOG-Ntx. The line on the graph is a straight line drawn from average values
using a mixed-effects model. FACT-C TOI, the Functional Assessment of Cancer Therapy-Colorectal Trial Outcome Index scale; FACT/GOG-
Ntx, the neurotoxicity subscale of the FACT/Gynecology Oncology Group-Neurotoxicity.
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